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Abstract
Background: Members of the PDGF family have been suggested as potential biomarkers for
papillary thyroid carcinomas (PTC). However, it is known that both expression and stimulatory
effect of PDGF ligands can be affected by inflammatory cytokines. We have performed a microarray
study in a collection of PTCs, of which about half the biopsies contained tumour-infiltrating
lymphocytes or thyroiditis. To investigate the expression level of PDGF ligands and receptors in
PTC we measured the relative mRNA expression of all members of the PDGF family by qRT-PCR
in 10 classical PTC, eight clinically aggressive PTC, and five non-neoplastic thyroid specimens, and
integrated qRT-PCR data with microarray data to enable us to link PDGF-associated gene
expression profiles into networks based on recognized interactions. Finally, we investigated
potential influence on PDGF mRNA levels by the presence of tumour-infiltrating lymphocytes.
Methods: qRT-PCR was performed on PDGFA, PDGFB, PDGFC, PDGFD, PDGFRA PDGFRB and a
selection of lymphocyte specific mRNA transcripts. Semiquantitative assessment of tumour-
infiltrating lymphocytes was performed on the adjacent part of the biopsy used for RNA extraction
for all biopsies, while direct quantitation by qRT-PCR of lymphocyte-specific mRNA transcripts
were performed on RNA also subjected to expression analysis. Relative expression values of PDGF
family members were combined with a cDNA microarray dataset and analyzed based on clinical
findings and PDGF expression patterns. Ingenuity Pathway Analysis (IPA) was used to elucidate
potential molecular interactions and networks.
Results:  PDGF family members were differentially regulated at the mRNA level in PTC as
compared to normal thyroid specimens. Expression of PDGFA (p = 0.003), PDGFB (p = 0.01) and
PDGFC (p = 0.006) were significantly up-regulated in PTCs compared to non-neoplastic thyroid
tissue. In addition, expression of PDGFC was significantly up-regulated in classical PTCs as compared
to clinically aggressive PTCs (p = 0.006), and PDGFRB were significantly up-regulated in clinically
aggressive PTCs (p = 0.01) as compared to non-neoplastic tissue. Semiquantitative assessment of
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lymphocytes correlated well with quantitation of lymphocyte-specific gene expression. Further
more, by combining TaqMan and microarray data we found a strong inverse correlation between
PDGFC expression and the expression of lymphocyte specific mRNAs.
Conclusion: At the mRNA level, several members of the PDGF family are differentially expressed
in PTCs as compared to normal thyroid tissue. Of these, only the PDGFC mRNA expression level
initially seemed to distinguish classical PTCs from the more aggressive PTCs. However, further
investigation showed that PDGFC expression level correlated inversely to the expression of several
lymphocyte specific genes, and to the presence of lymphocytes in the biopsies. Thus, we find that
PDGFC mRNA expression were down-regulated in biopsies containing infiltrated lymphocytes or
thyroiditis. No other PDGF family member could be linked to lymphocyte specific gene expression
in our collection of PTCs biopsies.
Background
The PDGF family of growth factor ligands and their recep-
tors have been extensively studied for more than two dec-
ades. PDGFC and PDGFD are the two most recently added
members of the PDGF family, consisting now of four lig-
ands, PDGFA, B, C and D, respectively, all signalling
through hetero- or homodimers of their receptors, PDG-
FRA and PDGFRB (for a review see [1] and [2]). PDGFC
and PDGFD will interact with their cognate receptor only
as homodimers, unlike PDGFA and PDGFB. PDGFC
interacts with and activates homodimers of PDGFRA as
well as heterodimers of PDGFRA and PDGFRB, but does
not interact with PDGFRB homodimers [3]. It is well
established by NIH/3T3 cells transformation assays that
PDGFB, but not PDGFA, is a potent transforming growth
factor [4,5], suggesting that the transformation process is
mediated by PDGFRB.
Differentiated carcinomas of thyroid follicular cell origin
include papillary carcinomas (PTC) and follicular carci-
nomas. These account for approximately 90% of thyroid
cancers and generally have a good prognosis, especially in
younger patients. When tumours show histological evi-
dence of de-differentiation (solid or insular structure,
nuclear atypia, mitotic activity, vascular invasion), exten-
sive extrathyroidal invasion in surrounding tissues and
residual tumour after surgery, or distant metastases, the
clinical behaviour is more aggressive and the prognosis
worse [6-8]. Undifferentiated thyroid carcinomas are
highly malignant and almost invariably fatal, and most
often arise in elderly patients. As differentiated, poorly dif-
ferentiated, and undifferentiated carcinomas all originate
from the thyroid follicular cell, thyroid carcinoma is an
attractive model for the study of tumourigenesis and
tumour progression.
Increased expression of PDGFB has been reported as a
potential diagnostic molecular marker for PTC [9].
Recently,  PDGFA  and  PDGFRA  were reported up-regu-
lated in thyroid carcinoma cell lines [10] and autocrine
activation of PDGFRA was suggested to play a crucial role
in the carcinogenesis of thyroid cells.
However, PDGF is in some cases found indirectly regu-
lated by inflammatory cytokines [11-13], and in PTC
tumour-infiltrating lymphocytes is frequently observed
[14,15]. Lymphocytic infiltration of adult PTC is com-
monly detected, and is also associated with reduced risk of
recurrence [14], indicating that this is some kind of
immune response. As many as 15% of tumours were
found to contain thyroiditis, an inflammation of the thy-
roid gland, in one large retrospective study [16]. Further-
more, patients with autoimmune thyroiditis generally
have improved disease-free survival [17,18]. It is still not
clear what triggers this lymphocytic infiltration of a large
fraction of PTCs, or how this presence of lymphocytes
within the tumour influences the expression of PDGF
family members in PTC.
Expression of the PDGFC protein in PTC has been docu-
mented. It has been demonstrated that PDGFC in PTC
specimens is expressed mainly in the cell membrane, the
cytosol and in the perinuclear area of the tumour cells,
and that the ~43 kDa non-SUMO1 modified form is the
predominant [19].
We here present data on mRNA expression level of the
complete PDGF family, i.e. PDGFA, PDGFB, PDGFC, and
PDGFD as well as their receptors, measured by TaqMan
qRT-PCR in five non-neoplastic human thyroid tissues,
ten differentiated (classic) and eight clinically aggressive
papillary thyroid carcinomas, the latter including seven
tumours with histologic evidence of poorly differentia-
tion. Seven biopsies contained a significant amount of
tumour-infiltrating lymphocytes and/or showed evidence
of thyroiditis. By integrating qRT-PCR data with microar-
ray data of the same tumour biopsies (four non-neoplastic
human thyroid tissues, nine classical (differentiated) and
seven clinically aggressive papillary thyroid carcinomas)
we were able to investigate potential molecular interac-BMC Cancer 2009, 9:425 http://www.biomedcentral.com/1471-2407/9/425
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tions and networks associated with PDGF and PDGFR
family member expression patterns.
Methods
Tissue specimens
Twenty-three thyroid tissue specimens were obtained
from patients undergoing thyroid surgery at Haukeland
University Hospital (Bergen, Norway). Informed consent
was obtained for the use of human tissue samples, and the
study was approved by the Regional Committee for Med-
ical and Health Research Ethics, Western Norway.
Tissue samples were taken from the surgical specimens
immediately after excision. One part of a sample was
directly snap frozen in liquid nitrogen, stored at -80°C
and later used for extraction of RNA. The adjacent part of
the sample was prepared for histologic analysis, as
described previously [20]. All biopsies were examined by
a histopathologist, and classified according to WHO crite-
ria (2004)[21].
All tumours were considered to originate from PTC, and
were selected to ensure subgroups with different clinical
behaviour. One tumour group comprised 10 differenti-
ated (classic) PTC of tumour stage pT1-pT4, according to
the pTpNM system [21]. This group of PTC comprised
biopsies from primary tumours of five classic PTC patients
without lymph node metastases in the neck or later
relapse, and biopsies from five patients with classic PTC
and lymph node metastases in the neck. A second group
comprised eight clinically aggressive PTC, including
patients in which macroscopic residual tumour was
present after surgery due to extensive local invasion into
surrounding structures (e.g. muscle, larynx, or trachea).
These biopsies included four primary tumours and three
lymph node metastasis with histologic evidence of poorly
differentiated carcinoma, and one relapse tumour in a
patient with synchronous distant metastases (Table 1).
Undifferentiated carcinomas were not included, except for
case 326 in which histologic evaluation showed PTC and
mainly poorly differentiated areas but also an undifferen-
tiated component. One of the biopsies, (247-IV), from the
primary tumour of a patient with distant metastases, con-
sisted primarily of non-neoplastic tissue but still con-
tained tumour tissue. A third group comprised five non-
neoplastic specimens (NT), taken from the contralateral
lobe of a tumour-bearing gland. All biopsies were used for
TaqMan qRT-PCR quantification of PDGF ligands and
receptors.
For integration of qRT-PCR and microarray data one of
the original biopsies were left out due to inadequate
amounts of RNA left for follow-up analysis (biopsy 317-
IV (differentiated PTC). Biopsy 242-NT (non-neoplastic
tissue) was not included in the original microarray series
[20]. This biopsy was excluded from lymphocyte quanti-
tation by qRT-PCR due to lack of RNA. Biopsies 181-NT
(non-neoplastic tissue) and 345-III (clinically aggressive
PTC) were not subjected to microarray analysis, but were
included for qRT-PCR quantitation of PDGF family mem-
bers and lymphocyte specific mRNAs.
Semiquantitative assessment of lymphocytes
Semiquantitative assessments of lymphocytes in each
biopsy were performed by a histopathologist on the adja-
cent part of the biopsy used for RNA extraction, as
described previously [20]. Four categories were created,
depending on the percentages of number of lymphocytes
relative to total number of cells, L0 = no, or only a few
lymphocytes, L1 = less than 10% lymphocytes, L2 =
between 10-50% lymphocytes and L3 = more than 50%
lymphocytes (Table 1).
RNA extraction and cDNA synthesis
Total RNA was extracted with Qiagen RNeasy minikit, as
recommended by the manufacturer. Two μg total RNA
was subjected to DNase I treatment in order to remove
any contaminating genomic DNA using TURBO DNase™
(Ambion), as recommended by the manufacturer. The
RNA quality and quantity was evaluated on Agilent bioan-
alyzer and by UV-spectrophotometry (OD 260/280),
respectively. Reverse transcription (RT) was performed
using TaqMan Reverse Transcription kit (Applied Biosys-
tems). Each RT-reaction contained approximately 100 ng
total RNA, 5 μl 10 × RT buffer, 2.5 μl 50 μM random hex-
amers, 1.25 μl MultiScribe reverse transcriptase (50 U/μl),
1 μl RNase inhibitor (20 U/μl), 4 μl 25 mM MgCl2, 10 μl
2 mM dNTP mixture (500 μM of each dNTP), and RNase-
free water to a final volume of 50 μl. The reaction was
incubated at 25°C for 10 min, followed by 48°C for 30
min, and finally 5 min at 95°C.
TaqMan qRT-PCR
Gene specific primers and TaqMan probes were either
Applied Biosystems AssayOnDemand or designed using
the Primer Express software version 1.0 (Applied Biosys-
tems) (Table 2). Designed amplicon spanned one exon
boundary. Quantification of specific mRNA was per-
formed using the ABI Prism 7700 or ABI 7900 instru-
ments (Applied Biosystems). Each qRT-PCR reaction
contained 5 μl cDNA, 12.5 μl TaqMan Universal Master
mix (Applied Biosystems), 300 nM sense and anti-sense
primer, 200 nM TaqMan probe in a total volume of 25 μl.
Each sample was run in triplicate. Cycling parameters
were 95°C for 10 min, followed by 40 cycles of 95°C for
15 s and 60°C for 1 min. Serial diluted standards were run
on the same plate and the relative standard curve method
was used to calculate the relative gene expression, as
described [22]. TaqMan ACTB detection reagent (Applied
Biosystems) was used as endogenous normalization con-BMC Cancer 2009, 9:425 http://www.biomedcentral.com/1471-2407/9/425
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trol to adjust for unequal amounts of RNA. None of the
samples displayed any signs of DNA contamination when
Reverse Transcriptase was omitted from the cDNA reac-
tion. Statistical comparisons were performed using the
Mann-Whitney rank sum test with the GraphPad Prism™
v.5.0 software (GraphPad Software, Inc.). P-values were
two-sided and considered significant when < 0.05.
For verification of lymphocyte-specific gene-expression,
we selected four targets for quantitation by qRT-PCR, lym-
photoxin beta (TNF superfamily, member 3) (LTB), inter-
leukin 2 receptor, gamma (severe combined
immunodeficiency) (IL2RG), FYN binding protein (FYB-
120/130) (FYB) and interleukin 32 (IL32). All assays were
Applied Biosystems Assay On Demand (see Table 2).
Table 1: Histopathological evaluation
Biopsy Group2 Histology1 L-score6 pTpNM-stage
(age, sex)
Relapse (years)3 Tumour4 Obs.
(years)
181-I PTC L0 T2AN0M0, (37, M) No PT 15
197-I PTC-FV, thyroiditis L2 T1BN0M0, (50, M) No PT 14
198-IV PTC, some histologic dediff. L0 T2AN1BM0, (13, F) No PT 14
219-II PTC(diff) PTC L0 T4AN0M0, (67, M) No PT 6.0 (dead)5
222-IV PTC L0 T1BN1BM0, (37, F) No PT 14
283-III PTC, thyroiditis L1 T2AN1BM0, (22, F) No PT 12
300-V PTC, squamous cell metaplasia L1 T3AN0M0, (43, F) No PT 11
317-IV PTC L0 T1N1AM0, (30, F) LN (9.1) LN (r) 11
328-V PTC L0 T2BN1AM0, (27, F) No PT 10
353-I PTC-FV L0 T3BN0M0, (70, M) No PT 9.0 (dead)
246-I PTC-R-M1 L0 T4AN1AM0, (79, F) LN, Lung (4.7) LN (r) 9.0 (dead)
247-IV PTC-PD-M1, thyroiditis L2 T4AN1AM1, (83, F) Lung metastases at diagnosis PT 0.4 (dead)
319-V PTC-PD L1 T4AN1AM0, (79, F) Residual tumour in trachea LN 2.0 (dead)
326-III PTC(agg) PTC-UD-M1 L0 T4AN1AM1, (72, M) Lung metastases at diagnosis PT 0.1 (dead)
345-III PTC-PD, squamous cell metaplasia L1 T1BN1BM0, (37, M) LN LN 3.4 (dead)
354-II PTC-PD L0 T4AN0M0, (80, F) No PT 10
367-I PTC-PD-R-M1 L0 T4AN0M1, (81, F) Lung metastases at diagnosis LN 1.3 (dead)
379-I PTC-PD L1 T4BN1BM0, (74, F) No PT 9.0
1:PTC: papillary thyroid carcinomas; FV: follicular variant; PD: poorly differentiated; UD: undifferentiated; R: relapse tumour; M1: presence of distant 
metastases. Representativity was assessed by histopathologic analysis from the immediate vicinity (neighbour section) to the biopsy used for 
extraction of total RNA. 2: PTC (diff): differentiated, with or without lymph node metastases; PTC (agg): poorly differentiated, or relapse tumour 
with synchronous distant metastases.
3: time from initial surgery to relapse (years). 4: PT: primary tumour; LN: lymph node metastasis in the neck, (r) = relapse. Biopsy 317 IV was not 
included in the microarray data. 5: Patient died from lung cancer not related to PTC. 6Semiquantitativ assessment of number of lymphocytes present 
in the biopsies: L0 = practically no lymphocytes, L1 = less than 10% of total number of cells, L2 = between 10-50% of total number of cells, L3 more 
than 50% of total number of cells. 7Section facing the part of the biopsy used for RNA extraction was classified as L0. Examination of two other 
sections taken from other parts of the same tumour revealed tumour-infiltrating lymphocytes (both classified as L1), also extending into the non-
neoplastic surrounding tissue.BMC Cancer 2009, 9:425 http://www.biomedcentral.com/1471-2407/9/425
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Integration of TaqMan and microarray data
TaqMan data was adjusted so that the median value of the
NT group was equal to one. Next, the dataset was log2
transformed, and inserted into a microarray dataset
described previously [20], performed on RNA extracted
from the exact same biopsies described above. Three out
of six PDGF ligands or receptors were present in both
datasets. To test the validity of combining qRT-PCR data
with microarray data, we compared expression profiles in
both analysis; A) (PDGFA (TaqMan) and PDGFA (micro-
array, probe id 435470), B) PDGFB (TaqMan) and PDGFB
(microarray, probe id 343320) and finally C) PDGFRA
(TaqMan) and PDGFRA  (microarray, probe id 52096).
The microarray slides were printed by The Norwegian
Microarray Consortium at The Norwegian Radium Hospi-
tal, using clones from the Unigene Image Consortium
40K set, representing approximately 15,000 human genes.
A further description of the microarray experiment is
given elsewhere [20]. TaqMan quantitation of a selection
of lymphocyte specific genes was performed on the biop-
sies described in Table 1, and in addition four non-neo-
plastic biopsies. Description of qRT-PCR primers and
probes is given in Table 2. Microarray data have been sub-
mitted to ArrayExpress http://www.ebi.ac.uk/arrayexpress
for public access.
Data analysis
Profile-similarity search was performed using J-Express
Pro v. 2.7 http://www.molmine.com/jexpress based on
the expression profile of each individual PDGF ligand and
receptors. From the 9262 expression profiles contained in
the dataset, we selected the 0.5% of all 9626 expression
profiles most similar to the real-time quantitated expres-
sion profile of each individual PDGF ligand or receptor
for further analysis (46 expression profiles in each selec-
tion). Subsequently, hierarchical clustering with average
linkage (weighted pair group method with arithmetic
mean, WPGMA) was performed on these selections.
Statistical analyses of the combined microarray and qRT-
PCR data were performed using the J-Express pro v. 2.7
software. In order to elucidate potential molecular inter-
actions and networks associated with PDGFC expression,
we used the result of the hierarchical clustering based on
the PDGFC similarity search which defined two tumour
groups (biopsies 181-I, 198-IV, 219-II, 353-I, 222-IV, 328-
V, 246-I, 354-II and 300-V in one group, and biopsies
197-I, 283-III, 247-IV, 367-I, 379-I, 319-V and 326-III in
the other). We then performed a significance of microar-
ray (SAM) analysis between the tumour groups [23], using
the complete dataset of 9262 individual expression pro-
Table 2: Primers and probes for TaqMan qRT-PCR
Gene Sequence (5'-> 3') Amplicon (bp) Genebank Acc.No
PDGFA
(+) TCGATGAGATGGAGGGTCG 71 NM_033023
(-) ACCCGGACAGAAATCCAGTCT
FAM-TGAGACCTCTGCACTTCCATCCCACG-TAMRA
PDGFB
Applied Biosystems Assay On Demand, Hs00234042_m1 80 NM_033016.1
PDGFC
(+) TATCTGATGAATATTTTCCTTCTGAACCAG 96 NM_016205
(-) GTAGCACTGAAGGACTCACAGCTTCT
FAM-TTCTGCATCCACTACAACATTGTCATGCCACAATTC-TAMRA
PDGFD
Applied Biosystems Assay On Demand, Hs00228671_m1 73 NM_033135.3
PDGFRA
(+) CAAGAGGAACAGACACAGCTCGCAGA 84 NM_006206
(-) CTGCTGGAACCCGTCTCAAT
FAM - CAAGAGGAACAGACACAGCTCGCAGA-TAMRA
PDGFRB
Applied Biosystems Assay On Demand, Hs00182163_m1 86 NM_002609.3
LTB2
Applied Biosystems Assay On Demand, Hs00242739_m1 78 NM_002341.1
IL2RG
Applied Biosystems Assay On Demand, Hs00173950_m1 76 NM_000206.1
FYB
Applied Biosystems Assay On Demand, Hs01061565_m1 123 NM_001465.3
IL32
Applied Biosystems Assay On Demand, Hs00992441_m1 85 NM_004221.4
Individual assays were either designed (PDGFA, PDGFC and PDGFRA) or ordered from Applied Biosystems, Assay On Demand, (PDGFB, PDGFD, 
PDGFRB, LTB2, IL2RG, FYB and IL32).BMC Cancer 2009, 9:425 http://www.biomedcentral.com/1471-2407/9/425
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files. SAM analysis performed in JExpress Pro v. 2,7 sorted
genes according to a False Discovery Rate (FDR), indicat-
ing in percentage whether or not the genes investigated
could be differentially expressed between the tumour
groups by chance. 289 expression profiles with FDR < 5
(less than 5% chance of genes falsely identified as differ-
entially expressed) were selected for further investigation
by Ingenuity Pathway Analysis (IPA) software (Ingenu-
ity).
Analysis of networks based on recognized interactions
Ingenuity Pathways Analysis was used in order to link
PDGFC-associated gene expression profiles into networks
based on recognized interactions. IPA was performed to
discern molecular and cellular functions and canonical
pathways on the basis of over-representation analysis, in
which, for each pathway, the fraction of PDGFC-associ-
ated gene expression profiles involved in that pathway
was compared to the fraction of human genes involved in
that pathway. For each pathway, the probability of
involvement of the respective number of PDGFC-associ-
ated genes was expressed as a P value; values of 0.05 were
taken to be significant.
Results
TaqMan qRT-PCR of PDGF
Three endogenous RNA expression controls, RPLP0 ribos-
omal protein (P0), glyceraldehyde-3-phosphate dehydro-
genase (GAPDH), and beta-actin (ACTB), were tested
against 18S ribosomal RNA (18S). ACTB was found com-
parable to 18S in expression across our specimens (data
not shown) and was therefore selected as endogenous
control.
When investigating mRNA expression between non-neo-
plastic tissue and PTCs, we found that PDGFA (p = 0.003),
PDGFB (p = 0.01) and PDGFC (p = p = 0.006) signifi-
cantly discriminated PTC from non-neoplastic tissue (Fig-
ure 1). By dividing the tumours into classical PTC and
more aggressive PTCs we found that PDGFC was the only
PDGF family member (including ligands and receptors)
that was significantly differentially expressed between the
two tumour groups (p = 0.006) (Figure 1). PDGFC expres-
sion was found significantly higher in the classical PTCs
than in the more aggressive PTCs. No other ligands or
receptors showed any significant differential expression
between classical PTCs and clinically aggressive PTCs.
However, PDGFRB expression was significantly higher in
the clinically aggressive PTC group as compared to non-
neoplastic tissue (p = 0.01). An overview of the relative
mRNA expression of all PDGF ligands and receptors in
each individual biopsy is illustrated in Figure 1.
TaqMan qRT-PCR of lymphocyte-specific gene expression
qRT-PCR quantification of the lymphocyte specific genes,
IL2RG, LTB, FYB and IL32 showed that seven biopsies
expressed these genes at a considerable higher level than
both the other PTCs and the non-neoplastic specimens
(Figure 2). This result correlated well with the results of
the semiquantitative assessment of infiltrating lym-
phocytes in all biopsies, with the exception of biopsy 300-
V (Table 1).
Semiquantitative assessment of tumour-infiltrating 
lymphocytes
Histopathological investigation revealed that 6 biopsies
contained tumour-infiltrating lymphocytes or thyroiditis
when examining a section facing the part of biopsy used
for RNA extraction. Biopsy 300-V was not found to con-
tain significant numbers of infiltrating lymphocytes on
this section, in conflict to the result obtained by qRT-PCR
on lymphocyte specific mRNA transcripts. Two other sec-
tions from other parts of this tumour were therefore exam-
ined retrospectively. Tumour-infiltrating lymphocytes
were found in both these sections, and it was also revealed
that the lymphocytes extended into the surrounding non-
neoplastic tissue (Table 1).
No biopsy were found to contain more than between 10-
15% of tumour infiltrating lymphocytes.
Expression profiling
The mRNA expression levels of PDGFA, PDGFB, and PDG-
FRA were assessed by qRT-PCR as well as by microarray
hybridization. Based on these data we tested the validity
of combining qRT-PCR data with microarray data directly.
Comparing expression profiles contained in both analyses
performed on identical total RNA, we found that the
expression profiles assessed by qRT-PCR or microarray
hybridization were highly similar (Figure 3).
Hierarchal clustering on 46 gene profiles selected by per-
forming an expression profile similarity search (0.5% of
9262), shows that tumours could be divided into two dis-
tinct groups separated from the non-neoplastic tissue
biopsies based on gene profiles highly similar to PDGFC,
with the majority of clinically aggressive PTCs confined in
one cluster. No other selection of expression profiles
based on similarity search could distinguish classical PTC
from clinically aggressive PTCs (Figure 4).
This characterization of two tumour groups was limited to
a supervised selection of genes with expression profiles
highly similar to that of PDGFC. For a broader characteri-
zation of these two groups, we investigate further gene
expression profiles that best discriminated these two clus-
ters of tumours by performing a Significance of Microar-
ray (SAM) analysis on the complete dataset of 9262 gene
profiles.
SAM analysis revealed 289 gene profiles that were signifi-
cantly differentially expressed between the two tumourBMC Cancer 2009, 9:425 http://www.biomedcentral.com/1471-2407/9/425
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mRNA expression of PDGF ligands and receptors Figure 1
mRNA expression of PDGF ligands and receptors. mRNA expression of PDGF ligands and receptors calculated relative 
to mRNA expression levels of the endogenous control (ACTB) in A) non-euplastic thyroid tissue (NT, green) and a collection 
of classical (PTC(diff), blue) and clinically aggressive PTCs (PTC(agg), red). All values were adjusted so that the median value of 
the NT group was equal to one. Bars indicate median value of each individual group. P-values (below) are from Mann-Whitney 
t-test between groups, as indicated. B) Relative mRNA expression of all PDGF ligands and receptors in each individual biopsy. 
PDGFA (red triangle), PDGFB (green triangle), PDGFC (yellow square), PDGFD (brown circle), PDGFRA (magenta diamond) 
and PDGFRB (blue triangle). All values were adjusted so that the median value of the NT group was equal to one.
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Expression of lymphocyte specific genes Figure 2
Expression of lymphocyte specific genes. A) Relative mRNA expression of four lymphocyte specific genes together with 
PDGFC expression as assessed by qRT-PCR. PDGFC (yellow circle), IL2RG (blue square), LTB (red square), FYB (green square) 
and IL32 (gray square) in all biopsies investigated. Serial number of biopsies is given below, non-neoplastic thyroid tissue 
(green), classical PTC (blue) and clinically aggressive PTC (red). B) Correlation between the semiquantitative histophatological 
examination and qRT-PCR of lymphocyte specific mRNA transcripts is illustrated. Categories is L0 = practically no lym-
phocytes, L1 = less than 10% of total number of cells, L2 = between 10-50% of total number of cells. IL2RG (blue square), LTB 
(red square), FYB (green square) and IL32 (gray square). Serial number of biopsies is given below, and the biosies are arranged 
according to the results from the histopatological assessment (L0, L1-L2), as illustrated.
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groups, with a false discovery rate equal to 5 (FDR < 5)
(less than 5% chance of genes falsely identified as differ-
entially expressed). This included 189 annotated genes
with known molecular functions and interactions, as
identified by Ingenuity Pathway Analysis software. Hierar-
chical clustering of these genes and biopsies shows that
the biopsies are divided into three groups. One of the
non-neoplastic tissue biopsies was included within one of
the tumour groups (Figure 4). IPA analysis revealed sev-
eral networks with known molecular interactions. The top
9 networks are listed in Table 3. Several of these networks
revealed molecular functions that could be coupled to
cells of hemapoetic origin. We combining network
1,2,3,5,7 and 9, and let IPA investigate molecular interac-
tions between these molecules. Figure 5 show the result-
ing networks. It is evident that NF- B and interferons are
connected to a majority of molecules within this selec-
tion. In addition, mRNA expression of several of these
genes, like FYB [24], IL32 [25], LTB [26], IL2 [27,28] and
IL2RG [29], is limited to hematopoietic tissue. Thus, it
seems that gene expression in one of these two tumour
groups is highly influenced by the presence of infiltrating
cells of hemapoetic origin.
This finding is in accordance with the histopathological
description of the tumour biopsies concerning presence
or absence of infiltrating lymphocytes (Table 1). By exam-
ining the expression levels of PDGFC within the classic
group of PTC, we found that three out of ten biopsies had
a relative modest up-regulated expression (Figure 2). Of
these three, one biopsy (198-IV) had some histological
de-differentiation, while the two other biopsies showed
histological evidence of thyroiditis.
Discussion
Differential expression of PDGF family members in PTC
has been reported as molecular markers for pathological
classification. Considering the different clinical nature
and outcome of classical and clinically aggressive/poorly
differentiated PTCs, new reliable markers separating the
two would certainly be advantageous. PDGFB was pro-
posed as a diagnostic marker for PTC in a microarray
mRNA expression study on PTC biopsies [9]. They found
that PDGFB was overexpressed in 81% of PTC cases stud-
ied. Although the overexpression was not dramatic (2-5
fold), immunostaining showed that it was significantly
increased at protein level, and it was concluded that plate-
let-derived growth factor could be a potential biomarker
for both PTC and follicular thyroid carcinoma (FTC). In
addition,  PDGFA  and  PDGFRA  were recently reported
overexpressed in two thyroid carcinoma cell lines, one
derived from PTC, the other from FTC [10]. In the latter
study, the authors imply that an autocrine activation of
PDGFRA may play a crucial role in the carcinogenesis of
thyroid cells. None of these reports claim to differentiate
between classical PTCs and the more aggressive and
poorly differentiated PTCs.
However, several reports describe how expression of
PDGF family members can be directly influenced by
cytokines, both at mRNA and protein level [11-13]. In
addition, T-lymphocytes derived from thyroid infiltrate
were shown to produce significantly higher amount of γ-
interferon than that of interferon producing cells isolated
from peripheral blood [30]. It is therefore plausible that
infiltrating lymphocytes in the tumour could influence
transcription of PDGF ligands or receptors. This needs to
be investigated in order to validate the use of PDGF family
members as molecular markers in PTC.
Protein expression of PDGFC in PTC has been character-
ized [19]. In PTC and in non-neoplastic thyrocytes
PDGFC protein is predominantly located in the mem-
brane, the cytosol and in the perinuclear area. Only in a
Quantification of PDGF expression level by Taman qRT-PCR and microarray hybridization Figure 3
Quantification of PDGF expression level by Taman qRT-PCR and microarray hybridization. Expression profiles of 
A) PDGFA, B) PDGFB and C) PDGFRA accessed by two different techniques, Taman qRT-PCR (blue square) and cDNA microar-
ray hybridization (magenta square) along the specimens investigated. Line is drawn between points for illustration purposes 
only. The three different groups of thyroid biopsy specimens are listed below the graph; Non-euplastic thyroid specimen (NT), 
differentiated PTC specimen (PTC (diff)) and poorly differentiated PTC (PTC (agg)).
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Hierarchical cluster analysis Figure 4
Hierarchical cluster analysis. A) Cluster analysis of genes selected by performing an expression profile similarity search for 
each of the PDGF family members. In each selection 0.5% of 9262 expression profiles with the highest similarity with each 
PDGF were selected (46 expression profiles). Normal thyroid tissue (green), classical PTCs (blue) and clinically aggressive 
PTCs (red). B) Cluster analysis based on 189 individual gene expression profiles selected by performing SAM analysis on the 
complete dataset of 9262 gene profiles between tumours grouped according to hierarchal clustering of 46 gene profiles with 
the highest similarity to PDGFC (biopsies 181-I, 198-IV, 219-II, 353-I, 222-IV, 328-V, 246-I, 354-II and 300-V in group 1(magenta) 
and biopsies 197-I, 283-III, 247-IV, 367-I, 379-I, 319-V and 326-III in group 2 (black). Normal thyroid tissue is labelled green. 
The colour scale below each figure illustrates the relative expression level as compared to the reference.
A)          B)
1. PDGFA
2. PDGFB
3. PDGFC
4. PDGFD
5. PDGFRA
6. PDGFRB
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Ingenuity network of molecular interactions Figure 5
Ingenuity network of molecular interactions. Ingenuity Path Designer Network of molecular interactions based on a set 
of 189 annotated genes with expression profiles derived from SAM analysis between tumours with or without presence of infil-
trating cells of hem poetic origin, focusing on 98 genes with expression values and 36 interconnecting molecules. Molecules are 
listed according to sub-cellular location (extracellular space, plasma membrane, cytoplasm, nucleus or unknown location). Fold 
change between Gr2 (lymphocytes or thyroiditis) as compared to Gr1 (no lymphocytes) is listed below each molecule. Red; 
Up-regulated in Gr2 as compared to Gr1. Green; Down-regulated in Gr2 as compared to Gr1. White; Interconnecting mole-
cules. Lines between molecules indicate a direct molecular connection between molecules.BMC Cancer 2009, 9:425 http://www.biomedcentral.com/1471-2407/9/425
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Table 3: Ingenuity Pathway Analysis, molecular interactions and networks
ID Molecules in Network Score Top Functions
1A L P ,   ANXA6, C1R, CD37, COL5A1, CXCL9, CXCL10, ERK, 
FCER1G, Ifn gamma, Ige, IGFBP5, IgG, IGHG1, IGL@, Igm, IL12, 
IL2RG, IL7R, Interferon alpha, JAG1, MAFB, MBL2, MHC Class 
II, Notch, NOTCH1, NOTCH3, NTN4, OXTR, PDGFC, SET, 
TGFB3, TNFRSF17, TNFSF13B, ZNF354C
44 Hematological System Development and Function, Tissue 
Development, Cellular Growth and Proliferation
2 ABCD3, CACYBP, CD3, CSF2RB, CXCL5, IFN Beta, IL1, 
IL32, IL23A, ISG15, JAK, KYNU, LCP2, LSP1, LTA, LTB, NF-
&kappa;B, NFAT complex, NFkB, NGFR, NPM1 (includes 
EG:4869), peptidase, PPIF, PSCDBP, REN, RIPK4, S100B, 
STAT4, TLR5, Tnf receptor, TNFAIP3, TYROBP, UBA7, 
VAV, VAV1
44 Hematological System Development and Function, Immune 
and Lymphatic System Development and Function, Tissue 
Morphology
3 ACTA2 (includes EG:59), Akt, Ap1, Calpain, CAPN3, CD4, 
CD53, COL4A2, COTL1, Cpla2, DOCK10, ENG, F Actin, FYB, 
HLA-DQB1, IL10RA, Integrin, LDL, MB, Myosin, NCK, Nfat, 
Pdgf, PER2, PER3, Pkc(s), Ras, SHROOM3, SUB1, SYF2, TCR, 
Tgf beta, TRA@, VCAM1, WIPF1
32 Cell-To-Cell Signaling and Interaction, Hematological System 
Development and Function, Immune and Lymphatic System 
Development and Function
4 AOF2, BAZ2A, BIRC5, Caspase, CBL, CCNA2, Cytochrome c, 
ELP3, GZMK, HCLS1, HIF1A, Histone h3, Hsp70, Hsp90, IFI27, 
IL2RB, Insulin, Mapk, NFKBIA, NR2F2, P38 MAPK, PFN1, PI3K, 
PLA2G7, Proteasome, RAD23B, RNA polymerase II, STAT, 
STAT1, STAT5a/b, UBD, Ubiquitin, Vegf, VIP, ZNF83
32 Cell Cycle, Cardiac Hypertrophy, Cardiovascular Disease
5 Actin, BST2, C1R, CAMSAP1, CAP2, CCL17, CXCL9, DUSP5, 
FCGR2B, HLA-DMA, HLA-DOA, HLA-DQB1, HLA-DQB2, 
HMGN3, IFI44L, IFNG, IL17F, IL18R1, IL18RAP, IL1B, IL23A, 
LCP1, MARCH5, NFYB, PDE4B, PLEK, PRPF40A, PXMP3, 
RAB8B, SF1, SMAD1, SP110, SPAG16, TREM2, TYMP
28 Immunological Disease, Immune Response, Connective Tissue 
Disorders
6 ABCD3, AHNAK, ARMCX3, ATF7IP, ATPase, BNIP3 (includes 
EG:664), C3, CLTC, COL4A2, COTL1, DAB2, ECM2, FBXO4, 
FBXO21, GRPEL1, HLTF, IFITM1, IKZF1, IKZF3, KIF1B, 
MYH6, NAE1, NEDD8, PPP2R4, retinoic acid, RNF10, SFTPC, 
SKP1, SMARCA4, SMARCA5, TERF1, TMEM150, UBE2M, 
VCAM1, VHL
22 Cell Cycle, Cellular Assembly and Organization, DNA 
Replication, Recombination, and Repair
7 BCL2L1, COL6A1, COL6A2, EGFR, ERBB2, FOXN2, FYB, 
GALNT10, GKAP1, GULP1, HBB (includes EG:3043), HGS, HP, 
HPR, ITGB1, KRT7, LTA, LTB, MIST, MYST1, NFIB, NPTN, 
NUP210, PLAC8, POLD1, PTPRA, PTPRS (includes EG:5802), 
SH3BGRL, SKAP1, THBS2, TP53, TRIM22, UPF3A, WAP, 
ZFP36L2
22 Immune and Lymphatic System Development and Function, 
Tissue Development, Cancer
8 ADSSL1, ANG, APOD, ARNT2, beta-estradiol, bilirubin, C3, 
CACNG1, CALCR, CGRRF1, ESR2, GARS, GYPA, HGF, IPO7, 
LCAT, MAMLD1, NPM1 (includes EG:4869), OCLN, PLEKHA4, 
POLD4, PRIM2, PTPN2, RAP1GAP (includes EG:5909), RBM9, 
RBM17, RGS3, RPL5, S100A13, SFRS10, SNAP25, STX4, STX1A, 
STXBP6, YWHAZ
18 Drug Metabolism, Molecular Transport, Small Molecule 
Biochemistry
9 AEBP1, CD79A, CD79B, CDC34 (includes EG:997), CDC45L, 
CDON, CHST10, EBF1, FSH, GATAD2A, GFI1, GLRX, H2-
M1, HLA-B, hydrogen peroxide, IDH2, IGHM, IGLL1, INSM1, 
KIAA0247, MAN2A1, MBD2, MIF, MYC, NEO1, PHKA2, 
SERINC3, TCF3, TERT, TGFBR3, UBE2L3, VPREB1 (includes 
EG:7441), YAF2, ZBTB7A, ZRANB1
18 Cellular Development, Hematological System Development 
and Function, Immune and Lymphatic System Development 
and Function
Ingenuity Pathway Analysis of 189 genes returned a number of networks of molecular interactions and functions. Here is listed the top nine 
networks. Molecules in each network is listed, Network Eligible Molecules appear in bold, while other molecules are in regular font. Score and Top 
Functions is as defined by Ingenuity Pathway Analysis.BMC Cancer 2009, 9:425 http://www.biomedcentral.com/1471-2407/9/425
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small fraction of cells (~10%) the PDGFC protein were
localized to the nucleus. The functional consequence of
the nuclear translocated PDGFC protein is yet not fully
investigated.
The non-neoplastic tissue biopsies consisted of thyroid
tissue taken from patients with thyroid carcinomas from
the contralateral side of the tumour-bearing gland. This
tissue does not in every respect constitute "normal" thy-
roid tissue. However, the reference RNA used in the
microarray hybridizations consisted of pooled RNA from
the thyroid gland of 65 individuals without known thy-
roid disease [20]. This enabled us to establish an approxi-
mate overview of differentially expressed genes in the
non-neoplastic group as compared to normal thyroid tis-
sue. We find that a number of genes are differentially
expressed in the non-neoplastic tissue compared to the
reference RNA, including both up- and down-regulated
genes. Interpretation of these data should, however, be
performed with caution. The reference RNA consists of
one pooled sample, and it is labelled with a different
fluorophore than the comparing samples. Still, analyzing
232 genes up- or downregulated in the non-neoplastic
group compared to the normal reference RNA by Ingenu-
ity Pathway Analysis software reveals a map of intermo-
lecular interactions that suggest a strong mitogenic
stimulation (data not shown). Thus, it seems that the
tumour is influencing gene expression in non-neoplastic
tissue, also when the tumour is situated on the contralat-
eral side. However, the number of differentially expressed
genes in these biopsies with respect to normal thyroid tis-
sue is relatively small, and gene expression between the
four non-neoplastic specimens is highly homogenous,
and very different from the expression profiles of the
tumour biopsies. In respect to the conclusions made in
this paper, we find it reasonable to believe that these biop-
sies represent normal mRNA expression in thyroid tissue.
We have previously used different techniques to investi-
gate global gene expression in a collection of PTCs,
including classical PTCs and clinically aggressive PTCs.
PDGFC was one of several candidates found up-regulated
in classic PTCs when performing a replica cDNA screen
[31]. We have since performed mRNA expression profil-
ing using cDNA microarrays in a series of differentiated
PTCs and clinically aggressive PTCs with and without
signs of infiltrating lymphocytes or thyroiditis, and iden-
tified a number of additional differentially expressed
genes in PTC as compared to non-neoplastic thyroid tis-
sue [20]. When performing supervised statistical analysis
on genes differentially regulated between the two tumour
groups and non-neoplastic biopsies, no member of the
PDGF family was included with statistical significance.
However, this could be due to the relatively low expres-
sion level of all members of the PDGF family in PTC, mak-
ing them difficult to quantitate by cDNA microarray
hybridization. We investigated this by analyzing the
expression of all known PDGF ligands and receptors by
qRT-PCR, in a collection of PTC biopsies previously char-
acterized with respect to global mRNA expression [31],
and combined these data for further analysis of possible
molecular interactions and networks. We found the
mRNA level of one or more PDGF ligands and/or recep-
tors significantly up-regulated in all tumour biopsies
tested except for biopsy 247-IV (histological analysis of
this biopsy revealed an overrepresentation of normal thy-
roid tissue). These results support previous findings by
others [9]. PDGFRA  was not significantly differentially
expressed between PTC and normal thyroid tissue. This
deviates from findings by others [10], although their
study was limited to the investigation of two cell lines
derived from one papillary and one follicular papillary
thyroid carcinoma. As we found PDGFRA highly up-regu-
lated in one PTC biopsy (353-I, a follicular variant of PTC)
and modestly up-regulated in another (300-V, containing
squamous cell metaplasia), it is certainly possible to find
biopsies from PTC patients with elevated expression of
PDGFRA, but this is not a consistent finding within our
selection of PTCs. However, this does not exclude the pos-
sibility of an autocrine activation of PDGF receptors as an
important factor in thyroid carcinogenesis. On the con-
trary, this could be supported by our results, i.e. signifi-
cantly up-regulated mRNA expression of PDGFA, PDGFB
and/or PDGFC in PTCs.
Hierarchical cluster analysis based on genes with expres-
sion profiles highly similar to that of PDGFC divided the
biopsies into two groups corresponding well with the his-
tological characterization of the tumours, although it did
not result in an absolute distinction between classical and
clinically aggressive PTCs.
SAM analysis between these two tumour groups resulted
in 289 expression profiles, more than three percentage of
the total number of expression profiles investigated, with
FDR<5. In comparison, SAM analysis between classical
PTCs and clinically aggressive PTCs resulted in only three
expression profiles with FDR<5 (data not shown).
The expression profiles revealed a significant overrepre-
sentation of genes whose expression is affected by
cytokines derived from cells of hemapoetic origin or
whose expression is limited to hematopoietic tissue. For
instance, FYB is a modulator of the expression of inter-
leukin-2 (IL-2), and is expressed in hematopoietic tissues
such as myeloid and T cells, spleen and thymus [24]. IL32
may play a role in lymphocyte activation, and is selec-
tively expressed in lymphocytes [25]. LTB is a cytokine
that may play a specific role in immune response regula-BMC Cancer 2009, 9:425 http://www.biomedcentral.com/1471-2407/9/425
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tion and is present on the surface of activated T, B, and
LAK cells [26].
Interleukin-32, or natural killer cell transcript 4 (NK4), is
induced by interleukin-2. Interleukin2-2 (IL2) is a power-
fully immunoregulatory lymphokine that is produced by
lectin- or antigen-activated T cells [27,28]. IL2RG, also
included in this selection, encodes the gamma subunit of
the interleukin-2 receptor (IL2R) [29]. By using IPA to elu-
cidate potential molecular interactions and networks, we
found that most genes differentially expressed between
the two tumour groups cold be coupled to Interferon-
alpha, beta and gamma, either directly or through media-
tors like NF- B (Figure 4). Thus, our results indicate that
the expression profiles with significant differentially
expression between the tumour groups are either genes
expressed in cells of hemapoetic origin or genes influ-
enced by cytokines, cytokines most probably produced by
infiltrating cells of hemapoetic origin.
This finding is in accordance with the histopathological
description of the tumour biopsies concerning presence of
lymphocytes (Table 1). By examining the expression lev-
els of PDGFC within the classic group of PTC, we found
that three out of ten biopsies had a relatively modest up-
regulated PDGFC expression (Figure 5). Of these three,
one biopsy (198-IV) had some histological de-differentia-
tion, while the two other biopsies showed histological evi-
dence of thyroiditis.
The semiquantitative assessments of lymphocyte infiltra-
tion performed on a thin section of the biopsies on the
adjacent part of the biopsy used for RNA extraction may
not reveal an accurate assessment of lymphocytes present
in the biopsy used for RNA extraction. However, it will
reveal presence of thyroiditis in the biopsy, and a high
level of lymphocytes in this section indicates that infiltrat-
ing lymphocytes is present in the particular biopsy. Direct
quantification of lymphocytes present in the biopsy used
for RNA extraction has not been possible. We therefore
used an indirect measurement of infiltrating lymphocytes
by quantitating mRNA expression of four lymphocyte-
specific genes, IL2RG, LTB, FYB and IL32. qRT-PCR quan-
tification of these genes showed that, with the exception
of biopsy 300-V, all biopsies found to contain infiltrating
lymphocytes in the adjacent part of the biopsy also
expressed higher levels of these lymphocyte-specific
genes. By a re-examination of biopsy 300 using sections
from other parts of the tumour, we found that the tumour
did in fact contain tumour-infiltrating lymphocytes that
also extended into the non-neoplastic regions. Thus, we
have a 100% correlation between the histopathological
examination and the qRT-PCR quantification of lym-
phocyte-specific mRNAs (Figure 5B). By comparing the
expression level of each of these lymphocyte-specific
genes to that of PDGFC, we find an inverse correlation in
all biopsies examined, with the exception of biopsy 300-V
(Figure 5A). Biopsy 300-V is a particular case in this col-
lection in that it is the only biopsy to be classified histo-
logical as squamous cell metaplasia. Expression levels of
PDGFA, PDGFB, PDGFRA and PDGFRB were all very dif-
ferent in biopsy 300-V compared to the rest of the PTC
biopsies, suggesting that this biopsy may be atypical (Fig-
ure 1B).
Our findings suggest that PDGFC expression in PTCs is
inversely correlated with the presence of infiltrating cells
of hemapoetic origin. We therefore propose that PDGFC
expression could be regulated at the mRNA level by
cytokines produced by these cells.
Conclusion
In summary, PDGFA, PDGFB, and PDGFC were found up-
regulated in PTC. Only PDGFC expression could differen-
tiate classical PTCs from clinically aggressive and poorly
differentiated PTCs, but gene expression profiling suggest
that this most probably is related to the presence of
tumour-infiltrating lymphocytes rather than to the current
classification of the tumours. Our results reflect how envi-
ronmental factors can influence the expression of growth
factor ligands or receptors within the cell or tissue studied,
and suggest that in-depth knowledge of such influences is
crucial when selecting reliable molecular diagnostic mark-
ers.
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